Clearside Biomedical, Inc. is an intellectual property holding, investment, and commercialization company with a portfolio intellectual property covering its proprietary suprachoroidal space (SCS) ocular drug-delivery platform and microinjector technology. Following its emergence from Chapter 11 in 2026, the Company operates with a recapitalized balance sheet, free of legacy liabilities, and is focused on rehabilitating or otherwise utilizing and monetizing its retained intellectual property.